Tarceva and International normalised ratio increased - a phase IV clinical study of FDA data

Summary:

International normalised ratio increased is reported as a side effect among people who take Tarceva (erlotinib hydrochloride), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Coumadin, and have Lung neoplasm malignant.

The phase IV clinical study analyzes which people have International normalised ratio increased when taking Tarceva. It is created by eHealthMe based on reports of 30,795 people who have side effects when taking Tarceva from the FDA, and is updated regularly.

What is Tarceva?

Tarceva has active ingredients of erlotinib hydrochloride. It is often used in lung cancer. eHealthMe is studying from 31,036 Tarceva users. Check the latest studies of Tarceva.

What is International normalised ratio increased?

International normalised ratio increased is found to be associated with 1,333 drugs and 1,727 conditions by eHealthMe. Check the latest studies of International normalised ratio increased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

30,795 people reported to have side effects when taking Tarceva.
Among them, 68 people (0.22%) have International normalised ratio increased.

Could Tarceva cause International normalised ratio increased?

Among these 68 people:

How long have people been on Tarceva when they have International normalised ratio increased? *

What is the gender of people who have International normalised ratio increased when taking Tarceva? *

female: 43.28 %
male: 56.72 %

What is the age of people who have International normalised ratio increased when taking Tarceva? *

What are other drugs people take besides Tarceva? *

What are other side effects people have besides International normalised ratio increased? *

Rashes (redness): 19 people, 27.94%
Diarrhea: 15 people, 22.06%
Weakness: 9 people, 13.24%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 7 people, 10.29%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 7 people, 10.29%
Anaemia (lack of blood): 6 people, 8.82%
Fatigue (feeling of tiredness): 6 people, 8.82%
Haemoglobin Decreased: 5 people, 7.35%
Pulmonary Alveolar Haemorrhage (acute bleeding): 5 people, 7.35%
Weight Decreased: 5 people, 7.35%

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 15 people, 22.06%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 8 people, 11.76%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 4 people, 5.88%
Embolism Venous (embolus may pass into the arterial system): 4 people, 5.88%
Lung Carcinoma Cell Type Unspecified Stage 0 (the lung cancer has not spread beyond the inner lining of the lung): 3 people, 4.41%
Pain: 3 people, 4.41%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 4.41%
Renal Cell Carcinoma (a kidney cancer): 3 people, 4.41%
Ovarian Cancer (cancer of ovary): 2 people, 2.94%
Pancreatic Carcinoma (pancreatic cancer): 2 people, 2.94%

* Approximation only. Some reports may have incomplete information.

Do you take Tarceva and have International normalised ratio increased?

- Check whether International normalised ratio increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tarceva:

Tarceva (31,036 reports)

International normalised ratio increased treatments and more:

International normalised ratio increased (40,071 reports)

How severe was International normalised ratio increased and when was it recovered:

International normalised ratio increased in Tarceva

Expand to all the drugs that have ingredients of erlotinib hydrochloride:

International normalised ratio increased and drugs with ingredients of erlotinib hydrochloride

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tarceva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with International normalised ratio increased:

International normalised ratio increased (1,333 drugs)

Browse all the conditions that are associated with International normalised ratio increased:

International normalised ratio increased (1,727 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on erlotinib hydrochloride (the active ingredients of Tarceva) and Tarceva (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.